Current treatments and perceptions of genital herpes: a European-wide view.
A European panel of physicians reviewed the current treatments and perceptions of recurrent genital herpes (GH) across the continent. The panel consisted of specialists in dermatology and venereology from France, Finland, Germany, Italy, Norway, Spain, Sweden and the UK. A wide variety of factors that influence GH management were considered, including different health delivery systems, funding and cultural differences. The poor awareness of GH among both the general public and physicians was highlighted. The effectiveness of GH management was then examined from a patient's viewpoint, including the confirmation of the diagnosis, information and counselling about GH, as well as prescriptions for treatment. It was agreed that both physicians and patients often feel uncomfortable about discussing the disease, and that a European-wide effort is needed to re-educate patients and physicians about GH. The panel identified clear and unmet needs to manage a patient with clinical recurrences and to attempt to reduce the risk of GH transmission. Finally, resiquimod, an immune response modifier, was considered as a potential treatment option for GH.
Strand
A
A
Department of Medical Sciences, Dermatology and Venereology, University Hospital, SE-751 85 Uppsala, Sweden. anders.strand@medsci.uu.se
Barton
S
S
Alomar
A
A
Kohl
P
P
Kroon
S
S
Moyal-Barracco
M
M
Munday
P
P
Paavonen
J
J
Volpi
A
A
D001291:Attitude of Health Personnel; D001294:Attitude to Health; D001364:Awareness; D003376:Counseling; D003695:Delivery of Health Care; D005060:Europe; D007722:Health Knowledge, Attitudes, Practice; D006558:Herpes Genitalis / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D012008:Recurrence